title: The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
abstract: 3,4-Dihydroxyphenylalanine (L-DOPA) treatment of Parkinson's disease (PD) is compromised by motor side effects, such as dyskinesia and non-motor problems, including psychosis. Because of the marked reduction in brain dopamine in PD and the resultant dopamine D2 receptor supersensitivity, it is impossible to use standard potent dopamine D2 receptor antagonists such as haloperidol to alleviate side effects without compromising the anti-parkinsonian benefits of L-DOPA. Haloperidol antagonizes D2 receptors with high affinity and slowly dissociates from D2 receptors (50% dissociation at 38min). We hypothesized that a rapidly dissociating D2 antagonist might allow some functional dopaminergic transmission and thus have a profile, with respect to reduction of dyskinesia and anti-parkinsonian effects, that was more useful therapeutically. The present study tested the principle of using a fast-off-D2 drug, CLR151 (50% dissociation at 23s) to modify L-DOPA actions in cynomolgus macaques with MPTP-parkinsonism. CLR151 (100mg/kg p.o.) reduced L-DOPA-induced dyskinesia and activity in the parkinsonian macaque by 86% and 52% respectively during peak action. CLR151 (100mg/kg) also reduced psychosis-like behaviour (i.e. reduced apparent visual hallucinations by 78%). Nevertheless, this dose of CLR151 significantly reduced the duration of anti-parkinsonian action of L-DOPA, ON-time (by 90%), and increased parkinsonian disability (by 57%). These data suggest that fast-off-D2 dopamine receptor antagonists, with D2-off-rate values close to those for CLR151, are unlikely to be useful in the treatment of dyskinesia and psychosis in PD. However, fast-off-D2 drugs could provide benefit if new congeners would have an even faster dissociation rate. Such drugs are now becoming available.
authors.affiliation: Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8.
authors.forename: James B
authors.initials: JB
authors.lastname: Koprich
authors.forename: Philippe
authors.initials: P
authors.lastname: Huot
authors.forename: Susan H
authors.initials: SH
authors.lastname: Fox
authors.forename: Keith
authors.initials: K
authors.lastname: Jarvie
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Lang
authors.forename: Philip
authors.initials: P
authors.lastname: Seeman
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Brotchie
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001522:Behavior, Animal / Q000187:drug effects; D002090:Butyrophenones / Q000494:pharmacology*; D003001:Cloning, Molecular; D018492:Dopamine Antagonists / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D007980:Levodopa / Q000009:adverse effects*; D020267:MPTP Poisoning / Q000188:drug therapy / Q000523:psychology; D008252:Macaca fascicularis; D008297:Male; D010302:Parkinson Disease, Secondary / Q000150:complications* / Q000188:drug therapy; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000978:Antiparkinson Agents; D002090:Butyrophenones; C583484:CLR151; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D007980:Levodopa